Pasithea’s Cancer Drug Redefines Endurance in a High-Stakes Fight

MIAMI, FL – June 30, 2026 – Pasithea Therapeutics (Nasdaq: KTTA), a clinical-stage biotechnology company, today announced promising interim data from a Phase 1 study of its drug candidate, PAS-004. The results suggest a potential breakthrough for patients with advanced, hard-to-treat cancers, demonstrating not only durable clinical activity but also a remarkably favorable safety profile that could set a new standard for a class of drugs known for their harsh side effects.

The drug, a next-generation MEK inhibitor, is being evaluated in patients with solid tumors driven by the MAPK pathway, a critical cellular signaling route frequently hijacked by cancer. The current cohort includes heavily pre-treated individuals, many of whom have already failed previous therapies targeting this same pathway, leaving them with a grim prognosis and few remaining options. The positive data has prompted Pasithea to expand the trial, a move that signals strong confidence in the drug's potential.

A New Strategy for Tolerability

The central challenge for MEK inhibitors—a cornerstone of treatment for cancers like BRAF-mutated melanoma—has always been a balancing act between efficacy and toxicity. While effective, existing approved drugs like trametinib and cobimetinib often come with a litany of debilitating side effects, including severe rash, gastrointestinal issues, and even cardiac or retinal toxicity. These adverse events can force patients to reduce their dose or stop treatment altogether, compromising outcomes.

Pasithea's PAS-004 appears to be charting a different course. The interim data from 34 patients reveals a safety profile that is, so far, exceptionally clean. All treatment-related adverse events were mild (Grade 1 or 2), with strikingly low rates of the rash (12%) and diarrhea (6%) that typically plague patients on MEK inhibitors. Critically, no cardiac or retinal toxicity has been observed, and for patients on the drug for nearly a year, rash and diarrhea were nonexistent.

"This level of tolerability, if it holds, is a game-changer," commented one oncologist who is not involved in the study. "For diseases that require chronic, long-term suppression, the ability to keep a patient on an effective dose without compromising their quality of life is the holy grail. It shifts the strategy from a short-term battle to a sustainable, long-term campaign."

Part of this unique profile may stem from the drug's design as a "macrocyclic" inhibitor with a long half-life of approximately 60 hours. This allows for convenient once-daily dosing and maintains stable drug levels in the body, avoiding the peaks and troughs that can exacerbate side effects while ensuring continuous pressure on the tumor's growth pathway.

Redefining Outcomes in Refractory Cancers

The most compelling aspect of the announcement is the durable clinical activity observed in a patient population that has largely been written off. The trial enrolled patients who had undergone a median of three prior lines of therapy, including ten who had already progressed after treatment with BRAF and/or MEK inhibitor combinations. For this group, the road has typically run out.

Yet, with PAS-004, several of these patients have achieved stable disease for over six months, and two have remained on the study for more than a year. This durability is particularly noteworthy. As Pasithea's Chief Medical Officer, Dr. Kartik Krishnan, pointed out, "The literature reports that patients with BRAF mutated cancer who progress on BRAF/MEK combination therapy have a median progression-free survival of approximately 5 months with rechallenge." The fact that PAS-004 is exceeding this benchmark in patients who have already failed similar treatments suggests it may be circumventing common resistance mechanisms.

"We have observed that a number of these patients who previously progressed on prior BRAF/MEK inhibitor treatment have demonstrated stable disease on PAS-004 for greater than six months, including two patients for over one year," Dr. Krishnan stated. "We believe that this demonstrates that PAS-004 is an active agent." This sustained disease control offers a profound new hope for patients facing a rapidly closing window of opportunity.

The Strategic Play: Building a Competitive Moat

Buoyed by these results, Pasithea is doubling down. The company announced a protocol amendment to continue dose escalation up to 52mg, a significant increase from the initial levels. This move, combined with the introduction of a new tablet formulation and a pilot "food effect" study, is a clear strategic play. It's not just about proving the drug works; it's about optimizing it for market dominance.

By exploring higher doses in the absence of dose-limiting toxicities, the company aims to find the optimal therapeutic window—the dose that maximizes efficacy while maintaining the drug's stellar safety profile. The food effect study will provide crucial real-world guidance for patients, clarifying whether the drug should be taken with or without meals to ensure consistent absorption.

This meticulous characterization is designed to build a competitive moat around PAS-004 in a market projected to reach over $4.6 billion by 2035. While extending the Phase 1 trial timeline, this investment provides a robust data package that could de-risk later-stage development and support a "best-in-class" label when negotiating with regulators and competing against established players like Novartis and Pfizer. It’s a strategy focused on building a resilient and competitive asset for the long haul.

Beyond a Single Battlefield: The Broader Potential

While the current trial focuses on advanced solid tumors, Pasithea's vision for PAS-004 extends to a wider battlefield. The drug is also being developed for neurofibromatosis type 1 (NF1), a genetic disorder that causes tumors to grow on nerves. In NF1, which often affects children and requires lifelong management, a drug's long-term safety profile is not just a benefit—it's a necessity. The very features that make PAS-004 promising in cancer—its high tolerability and potential for chronic dosing—make it an especially compelling candidate for NF1 and other related genetic conditions known as RASopathies.

Current approved treatments for NF1, while effective, still carry the baggage of MEK inhibitor-related side effects. A therapy that could offer comparable or superior tumor control with a fraction of the toxicity would represent a significant leap forward for this patient community. By targeting a fundamental biological pathway, PAS-004 has the potential to become a versatile tool, addressing unmet needs across a spectrum of diseases all linked by a common aberrant signal. This broad applicability underscores the strategic importance of developing a drug that is not only powerful but also sustainable for the human body over the long term.